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A NOVEL STRATEGY FOR SELECTIVE DEPLETION OF HOST-REACTIVE
DONOR LYMPHOCYTES BY PHOTODEPLETION IS EFFICIENT AT CLIN-
ICAL SCALE CONDITIONS AND PRESERVES foxp3 REGULATORY T
CELLS
Mielke, S.1, Rezvani, K.1, Fellowes, V.2, Venne, A.3, Solomon, S.R.1,
Fan, Y.2, Hensel, N.1, Carter, C.S.2, Read, E.J.2, Barrett, A.J.1 1.
Allogeneic Stem Cell Transplantation Section, National Institutes of
Health, Bethesda, MD; 2. Department of Transfusion Medicine, Na-
tional Insitutes of Health, Bethesda, MD; 3. Celmed Biosciences Inc,
Saint-Laurent, QC, Canada.
Using an anti-CD25 immunotoxin (IT) for ex vivo selective
depletion (SD), we recently showed that removal of host-reactive
donor T cells is clinically feasible. Nevertheless, there was a con-
cern that the removal of CD4 CD25 foxp3 regulatory T cells
(Tregs) by CD25-IT might favor GVHD. We therefore investi-
gated photodepletion (PD), an alternative approach whereby allo-
activated cells are labeled with the photosensitizing rhodamine-
based dye TH9402, and exposure to light eliminates cells retaining
the dye. PD may offer the possibility of conferring donor immu-
nity without GVHD, permitting allo-SCT without the need for
post-graft immunosuppression. Stimulator cells from human sub-
jects were prepared from leukapheresis MNCs and cultured using
anti-CD3 and 100 IU IL-2. Responder cells (leukapheresis MNCs)
from HLA-mismatched volunteers were cocultured 1:1 with irra-
diated stimulators for 3 days. Cultured cells were incubated in
TH9402 (5.0 and 7.5 microM), followed by exposure to 514 nm
light in the PD light source (Celmed) at a cell concentration of 5
106/ml in FEP plastic bags (American Fluoroseal). Results were
compared with the established small scale standard method. De-
pletion efﬁcacy was studied by FACS and MLR. Effects on Tregs
were investigated using foxp3 RT-PCR and intracellular foxp3
staining. In two large-scale experiments using cells from two do-
nors, both the standard small-scale conditions and the large-scale
conditions resulted in a 9–18-fold and 21–42-fold reduction in
alloreactivity when compared to the untreated MLR control on
day 1 and day 4 after PD. Third-party responses were main-
tained. Effective depletion was observed despite the fact that a
small fraction of CD25 cells (2.7–3.3% of CD4 cells) were still
detectable by FACS on day 4 after PD. RT-PCR for foxp3 in
CD4-selected cells from the ﬁnal SD product showed that a frac-
tion of foxp3 mRNA was conserved. Intracellular foxp3 staining
showed that foxp3 Tregs persisted after PD, and represented 6%
of CD4 cells in untreated responder cells versus 2.1–4.4% of
CD4 cells in the SD product. PD is feasible under large scale
conditions and results in efﬁcient removal of alloreactive lympho-
cytes, while conserving desirable third-party responses. Use of PD
to selectively deplete donor stem cell transplants may further
mitigate the risk of GVHD by conserving Tregs. (This work was
supported in part by a collaborative research and development
agreement between the NHLBI/NIH and Celmed Biosciences
Inc.).
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POST-THAW WASHING PRIOR TO TRANSPLANTATION OF UMBILICAL
CORD BLOOD UNITS (UCB) THAT WERE DEPLETED OF PLASMA BUT
NOT OF RED BLOOD CELLS
Chow, R.1, Nademanee, A.2, Rosenthal, J.2, Karanes, C.2,
Graham, M.3, Tan, P.4, Jaing, T.-H.5, Gjertson, D.6, Petz, L.1 1.
StemCyte International Cord Blood Center, Arcadia, CA; 2. City of
Hope National Medical Center, Duarte, CA; 3. University of Arizona
Medical Center, Tuscon, CA; 4. Mount Elizabeth Hospital, Singapore,
Singapore; 5. Chung Gung Memorial Hospital, Linko, Taiwan; 6.
UCLA Medical Center, Los Angeles, CA.
Washing after thawing of frozen UCB used for hematopoietic
stem cell transplantation (HSCT) is widely practiced for the pur-
pose of removal of the cryoprotectant DMSO and free hemoglobin
from lysed red cells; however, frozen peripheral blood stem cells
with similar loads of free hemoglobin and DMSO are often thawed
and infused directly without washing. Recently, similar clinical
outcomes were seen with the standard red cell depleted (RCD)
UCB, whether washing was employed after thawing or not. How-
ever, no data exist on the utility of post-thaw washing for UCB that
were depleted of plasma (PD) but not depleted of red blood cells.
A retrospective analysis was performed on the outcomes of 84
patients in remission without history of prior transplants, who
received either washed (W; n  43) or non-washed (NW; n  40)
PD UCB units for HSCT. Adverse events of any grade occurring
more than once during infusion include hemoglobinuria (9 NW, 1
W), hypertension (6 NW, 4 W), hives (1 NW, 1 W), nausea/vomit
(2 NW) and dyspnea (1 NW, 1 W). One patient developed seizure
and encephalopathy following infusion of a NW PD UCB that
resolved without any sequelae, although relationship to UCB in-
fusion was uncertain. Total nucleated cell recovery after thawing as
reported by transplant centers is higher for NW (median 95% vs
75%). Unadjusted cumulative incidence (U.C.I.) of neutrophil en-
graftment was similar for both groups, 91  5% for NW (n  36)
versus 93 4% for W (n 41), but median time to neutrophil (20
vs 26 days) and platelet engraftment (platelet 20K 47 vs 55 days and
platelet 50K 55 vs 63 days) occurred earlier for NW. U.C.I. for
platelet 20K engraftment was higher for NW (n  28; 92  6%)
than W (n  39; 75  7%). Acute grade III-IV GvHD were 10%
(NW) and 19% (W), and extensive chronic GvHD were 0% (NW)
and 22% (W). TRM were 18  6% (NW) and 20  7% (W), with
relapse rate for malignant cases at 11  7% for NW and 25  8%
for W. One-year OS was 75  7% (n  40) versus 72  8% (n 
43), and 1-year DFS was 69  10% (n  23) versus 54  9% (n 
34) for NW and W, respectively. No clear beneﬁts of post-thaw
washing for PD UCB prior to HSCT was found, except for the
anticipated lower incidence of transient hemoglobinuria. HSCT
with NW PD CBU was at least as efﬁcacious as that using W PD
units with respect to neutrophil engraftment, TRM, relapse rate,
1-year OS, and DFS. Moreover, washing may have a negative
impact on U.C.I. of platelet engraftment and the speed of neutro-
phil and platelet engraftment.
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ACTIVATION AND ENHANCEMENT OF EX VIVO (EvE) EXPANDED
CRYOPRESERVED CORD BLOOD (CB) NATURAL KILLER (NK) CELLS,
CYTOLYTIC POTENTIAL, AND NK RECEPTOR (NKR) EXPRESSION: PO-
TENTIAL ROLE FOR CB NK IN ADOPTIVE CELLULAR IMMUNOTHERAPY
(ACI)
Ayello, J.1, Satwani, P.1, Lomazow, W.1, van de Ven, C.1, Roman, E.1,
Shereck, E.1, Baxi, L.2, Kurtzberg, J.3, Cairo, M.S.1 1. Dept of Pedi-
atrics, Columbia University, NY, NY; 2. Obstetrics and Gynecology,
Columbia University, NY, NY; 3. Pediatrics, Duke University, NY, NY.
NK subsets exhibit differential NKR proﬁles including KIR,
C-lectin (NKG2), and natural cytotoxicity receptors (NCR) in-
volved with tumor recognition (Farag et al, Blood, 2002). NKRs
such as NCR (NKp44, NKp46) and NKG2 surface receptors
NKG2D induce NK cell activation and mediated cytolysis (Mor-
etta et al, Curr Opin Immunol, 2004). CB is limited by the absence
of available donor effector cells for infusion after UCBT (Cairo et
al Transfusion, 2005). We demonstrated the ability to EvE in short
term culture with IL-2, IL-7, IL-12, and anti-CD3 (ABCY) cryo-
preserved, thawed, recryopreserved, rethawed, and EvE (CTCTE)
CB with increases in CD3/16/56 bright/dim subsets expressing
KIR3DL1, KIR2DL1/S1, KIR2DL2, and CD94/NKG2A (Ayello/
Cairo et al, BBMT, 25a, 2004). We now compared short-term with
prolonged cultures (4–10 days) on expansion, maturation, and
expression of NCR, NKG2, KIR, and cytolytic mechanisms in
CTCTE CB. Rethawed CB cells (Kurtzberg/Cairo, Transfuison,
2005) were cultured (2–10 days) in media alone or with anti-CD3
(50 ng/ml), IL-2 (5 ng/ml), IL-7 (10 ng/ml), and IL-12 (10 ng/ml).
NKR expression (CD94, NKG2C, NKG2D, NKp44, NKp46,
KIR2DS4) and intracellular perforin and granzyme B activity were
determined by ﬂow cytometry. Europium release assay measured
NK and LAK cytotoxicity. NK activating KIR2DS4 was increased
day 10 versus 2 in ABCY in both CD3/16/56 dim/bright subsets
(16.9 0.4 vs 2.1 0.2% and 22.3 0.3 vs 0.9 0.2%, P .001,
respectively). CD94/NKG2D expression was increased day 7 ver-
sus 2 in ABCY EvE (41.4  0.43 vs 23.7  2.0%, P  .001). NK
(CD3/16/56dim) KIR3DL1 subset was increased day 10 versus
2 (38.3  2.8 vs 18.9  6.37%, P  .05). CD3/16/56dim
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NKp44 subset NCR expression was decreased day 10 versu 2 in
ABCY (15.2  0.7 vs 27.2  0.7%, P  .001). CD3/16/56 dim
NKp46 expression was decreased following day 10 versus 2 (8.5 
0.2 vs 23.5  1.2 %, P  .001). Granzyme B was increased from
day 2 to 10 (25.8 1.8 vs 45.1 1.7%, P .0001) yet perforin was
decreased in ABCY day 10 versus 2 (55.7  1.8 vs 84.3  1.3%,
P  .001). ABCY CB NK and LAK cytotoxicity was increased day
10 versus 2 (NK: 71.5  1.6 vs 53.8  10.3%, P  .001; LAK:
63.2  0.24 vs 31.8  1.8%, P  .001). In summary, CB MNC
may be thawed at UCBT, CT at a later date, EvE and activated for
7–10 days to yield viable NK subsets. ABCY 10 day EvE CB
yielded increased NK KAR (CD56dim/bright) and granzyme B
expression but decreased NK C-lectin CD94/NKG2D, NCR
NKp44 and NKp46, and perforin expression.
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LANTCET: NOVEL LASER NANOTECHNOLOGY FOR GRAFT PURGING
Lapotko, D.1, Aleinikova, O.2, Lukianova, E.1, Shman, T.2,
Savitcky, V.2, Oraevsky, A.3 1. Luikov Heat and Mass Transfer Insti-
tute, Minsk, Belarus; 2. State Pediatric Center for Oncology and He-
matology, Minsk, Belarus; 3. Fairway Medical Technologies, Inc, Hous-
ton, TX.
We introduce a novel ex vivo method, Laser-Activated Nano-
Thermolysis Cell Elimination Technology (LANTCET), for
selective killing of individual tumor cells in bone marrow and
peripheral blood samples. LANTCET assumes cell-speciﬁc de-
livery of gold nanoparticles (GNP) into tumor cells and irradi-
ation of cell sample with laser pulse. Nanoparticles absorb laser
pulse, instantly heat, and produce micro-bubbles of vapor that
damages cells. This process is toxic-free, takes microseconds,
and is localized in individual cells, thus being safe for surround-
ing normal cells. The mechanism of cell-speciﬁc delivery of
GNP to target tumor cells uses primary and secondary mono-
clonal antibodies for binding the GNP to cell membrane and
further cauterization of GNP into compact groups. In experi-
ments, we used human ALL and AML and normal bone marrow
samples to evaluate efﬁcacy and safety of LANTCET. Accumu-
lation of GNP in cells was studied with ﬂow cytometry, ﬂuo-
rescent microscopy, and electron microscopy. Using specially
developed incubation protocols for 30-nm GNP, we provided
controlled forming of GNP clusters in tumor cells only, while
only single GNP were discovered in normal stem cells due to
non-speciﬁc binding. After incubation with GNP, the cell sam-
ples were irradiated with single laser pulse (532 nm, 10 ns,
0.5–1.0 J/cm2). Cell damage levels were measured for tumor and
normal cells with ﬂow cytometry (necrosis and apoptosis). At
speciﬁc laser ﬂuence total damage of ALL cells and 84% of
AML cells was achieved while among normal cells only 16%
were damaged after single laser pulse. This method is now at the
stage of the development of an experimental system for purging
transplants (grafts) of bone marrow and blood.
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THE PLATELET COUNT AT INITIAL AUTOLOGOUS PERIPHERAL BLOOD
STEM CELL HARVEST DOES NOT INFLUENCE PLATELET ENGRAFTMENT
AFTER STEM CELL TRANSPLANTATION
Aljitawi, O.1, Merkel, D.1, Trieu, K.1, Deauna-Limayo, D.1,
Ganguly, S.1, Bodensteiner, D.1, Divine, C.1, Skikne, B.1 The Univer-
sity of Kansas Medical Center, Kansas City, KS.
Many factors inﬂuence marrow recovery after autologous pe-
ripheral blood stem cell (PBSC) transplantation. The status of
the patient’s bone marrow function at harvesting may certainly
be an important factor. This study was conducted to evaluate
whether the platelet count at the initial stem cell harvest pre-
dicts time to platelet and neutrophil engraftment after trans-
plantation. The data of 96 consecutive patients who underwent
autologous PBSC transplantation between 2001 and 2004 were
reviewed. Data collected included diagnosis, date of diagnosis,
date of ﬁrst harvest, number of harvests to obtain prerequisite
number of CD34 cells, platelet and neutrophil counts at initial
harvest, and time to platelet and neutrophil engraftment. An
adequate target CD34 cell number was 	2.5  106/kg patient
weight. The majority of patients had multiple myeloma (45%),
followed by non-Hodgkin’s lymphoma (25%), Hodgkin’s Dis-
ease (17%), and others (13%). Two collection groups were
identiﬁed, 1 group requiring only 1 collection period and a
second group requiring more than one. Seventy-one patients
required 1 collection period of up to 5 consecutive days of stem
cell harvest. The average harvest time to obtain the required
numbers of stem cells was 3.16 days. The average platelet count
at initial harvest was 187,000/uL. Average time to platelet en-
graftment was 19.2 days and to neutrophil engraftment was 11.6
days. Sixteen patients required 	1 peripheral stem cell collec-
tion periods. For these patients, the time to platelet engraftment
was 22.7 days and to neutrophil engraftment was 12.2 days.
Nine patients did not have platelet engraftment because they
either died before platelet engraftment or their platelets did not
engraft secondary to relapse of disease. The average initial count
of this group was 187,000/uL, similar to the other patient
group. There was no correlation between platelet count at ﬁrst
harvest and time to platelet engraftment (r  0.12141). Plate-
let engraftment time did not correlate with neutrophil engraft-
ment (r  0.1). In conclusion, patients who required 	1 pe-
ripheral stem cell collection period, have delayed engraftment of
platelets and to lesser extent delayed neutrophil engraftment,
when compared to patients requiring only one collection period.
297
AUTOMATED SEPARATION OF CORD BLOOD MNC FRACTION IN A
CLOSED SYSTEM: THERMOGENESIS AXP SYSTEM
Dobrila, L.1, Jiang, S.1, Chapman, J.2, Marr, D.2, Kryston, K.2,
Rubinstein, P.1 1. National Cord Blood Program at New York Blood
Center, New York, NY; 2. ThermoGenesis Corp, Rancho Cordova, CA.
Background: Compliance with current good tissue practices
(cGTP) is essential to achieving product uniformity in cord blood
banks. A critical step in the processing of cord blood is volume
reduction, to allow standardization of the freezing rate and help
maintain stem cell viability and to optimize liquid nitrogen storage
space utilization. To enable instrumented cord blood volume re-
duction, ThermoGenesis developed the AutoXpress™ (AXP™)
System consisting of a microprocessor-controlled device and dis-
posable closed blood bag set. The AXP™ ﬁts standard refrigerated
blood bank centrifuge buckets. Cord blood is transferred to the bag
set and centrifuged. With the AXP™ system, up to 6 units of cord
blood can be processed at one time with a standard blood bank
centrifuge. Study Design: A study was performed to determine the
efﬁciency with which cord blood hematopoietic progenitor cells
can be recovered, using the CD34 cell marker and colony-forming
unit (CFU) counts as indices. Twenty-three consecutive cord
blood units were processed with the AXP™. The blood volume,
hematocrit, total nucleated cells (TNC), mononuclear cells
(MNC), CD34 cells, and colony-forming units were determined
in samples from cord blood units before and after AXP™ separa-
tion. Results: Results are presented as the mean  S.D. (N  23)
for all values. The AXP™ process achieved mononuclear (MNC)
fraction volumes of 19.7  0.3 ml with a ﬁnal average hematocrit
of 29.8  2.6%. The recovery was 98.2  8.0% (CD34 cells),
94.6  7.0% (CFU), 97.9  4.9% (MNC), and 84.8  9.2%
(TNC). Less than 1% of TNC were found in the excess plasma
bag. Fifteen percent of TNC were lost and recovered in the red cell
bag, and were mostly granulocytes. Less than 0.5% of the CD34
cells were found in the RBC bag. Conclusions: The AXP™ cord
blood volume reduction process automatically, efﬁciently, and re-
producibly separated cord blood mononuclear cells, CD34 cells,
and CFU activity. It achieved high recoveries (	94%) in a closed
system without requiring hetastarch. The volume target was de-
livered into the freezing bag with high precision. Thus, AXP™ can
meet the volume reduction quality standard for automated cord
blood processing.
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